Bioventus (NASDAQ:BVS) Announces FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus earnings per share estimate of 0.780. The company issued revenue guidance of $590.0 million-$595.0 million, compared to the consensus revenue estimate of $604.6 million.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BVS. Canaccord Genuity Group reduced their price objective on shares of Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings raised shares of Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, Bioventus currently has an average rating of “Buy” and a consensus target price of $16.60.

Bioventus Stock Performance

Shares of NASDAQ BVS traded down $2.03 during trading on Tuesday, reaching $11.12. 392,065 shares of the stock traded hands, compared to its average volume of 520,375. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.69 and a quick ratio of 1.17. The stock has a market capitalization of $935.33 million, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 1.87 and a beta of 0.64. Bioventus has a 52-week low of $6.47 and a 52-week high of $15.89. The company has a 50-day moving average of $13.68 and a 200-day moving average of $10.90.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.17. Bioventus had a return on equity of 28.08% and a net margin of 9.36%. The company had revenue of $142.44 million for the quarter. Analysts forecast that Bioventus will post 0.79 EPS for the current fiscal year.

Key Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching analyst expectations and increasing from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS beat or in-line result. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its fiscal 2026 adjusted EPS outlook of $0.75 to $0.79, broadly consistent with the $0.78 consensus estimate. The company’s earnings performance also benefited from debt paydown and lower interest costs. Bioventus Fiscal 2026 Outlook
• Neutral Sentiment: Third-quarter revenue was $142.44 million, while return on equity was 28.08% and net margin was 9.36%. Investors are assessing whether improving profitability can offset slower top-line growth. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut fiscal 2026 revenue guidance to $590 million-$595 million from a level implied by the prior outlook, below the $604.6 million consensus estimate. The reduction signals weaker operational growth and was the main source of investor pressure. Bioventus Sales Miss and Outlook Cut
• Negative Sentiment: Commentary characterized earnings growth as being driven more by debt reduction than by underlying operations, raising concerns about the sustainability of profit improvement if revenue momentum remains limited. Bioventus Earnings Growth and Revenue Outlook

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.